Related by context. All words. (Click for frequent words.) 71 disease progression 64 tumor recurrence 64 metastasis 62 leukemic cell 62 distant metastasis 62 EGFR 62 tumorigenesis 61 Aβ 61 telomere shortening 61 bone metastasis 61 IL 1beta 60 decitabine 60 Notch1 60 malignancies 60 cyclin E 60 TGF β 60 clusterin 60 tumor shrinkage 60 myeloma cells 60 colorectal tumors 60 metastatic disease 60 EGF receptor 59 STAT3 59 EGFr 59 lung metastasis 59 imatinib 59 tumors 59 IGF 1R 59 complete cytogenetic response 59 engraftment 59 IFN gamma 59 tumor regression 59 CTGF 59 WT1 59 malignant transformation 59 cisplatin 59 overexpression 59 Bcl xL 59 metastatic 59 calcitriol 59 Cyclin D1 59 osteoclast activity 59 RANKL 59 Akt activation 59 c MYC 58 metastases 58 lymph node metastasis 58 PDGFR 58 remyelination 58 cytotoxicity 58 tumor 58 osteopontin 58 epithelial tumors 58 lung tumors 58 colorectal carcinoma 58 apoptotic pathway 58 Smad3 58 NSCLC 58 GSK3 58 activin 58 PSADT 58 Aß 58 mRNA expression 58 mammary tumors 58 transgene expression 58 imatinib therapy 58 tumor cells 58 activating mutations 58 neurite outgrowth 58 sarcomatoid 58 TNF α 58 MDM2 58 liver metastases 58 interferon alpha 58 topotecan 58 COX2 58 antiangiogenic 58 apoptotic cell 58 enzymatic activity 58 chemoresistance 58 PGE2 58 Wnt signaling 58 metastatic cancer 57 pCR 57 downregulation 57 BCR ABL 57 dasatinib 57 neurologic progression 57 E#F# 57 MAPK pathway 57 factor receptor 57 CLL cells 57 sunitinib 57 ovarian carcinoma 57 apoptotic 57 bone resorption 57 metastatic lesions 57 cellular senescence 57 N cadherin 57 androgen deprivation 57 neoplasia 57 platelet aggregation 57 GRP# 57 c myc 57 metastatic prostate cancer 57 mutant huntingtin 57 apoptotic cells 57 Clusterin 57 metastatic renal cell carcinoma 57 sorafenib 57 erlotinib Tarceva 57 cyclin D1 57 p# activation 57 VEGFR2 57 ERK1 2 57 hepatocellular carcinoma 57 mutated KRAS 57 azacytidine 57 fulvestrant 57 brain metastases 57 VEGF 57 TNFalpha 57 neuronal differentiation 57 lung fibrosis 57 androgen receptor 57 pancreatic adenocarcinoma 56 leukemic cells 56 mitochondrial function 56 apoptosis 56 TACE 56 Aurora kinase 56 interferon beta 56 bortezomib 56 TNFa 56 neuronal cell 56 DNA methylation 56 imatinib Gleevec 56 distant metastases 56 trastuzumab 56 iNOS 56 β catenin 56 neurotrophic 56 Akt1 56 neuroendocrine tumors 56 neovascularization 56 complete cytogenetic 56 bone metastases 56 oncoprotein 56 mTOR signaling 56 prostate cancer CaP 56 NF kB pathway 56 cetuximab 56 heavily pretreated 56 FOXP3 56 EZH2 56 neoadjuvant therapy 56 estrogen receptor 56 renal cell carcinoma 56 antitumor activity 56 Hedgehog signaling 56 Smad7 56 prostate tumor 56 phosphorylation 56 pro apoptotic 56 prolongs survival 56 anti leukemic 56 fibrotic 56 Mcl 1 56 beta catenin 56 hypomethylation 56 mitoxantrone 56 xenograft models 56 mitogen activated protein kinase 56 TNF alpha 56 cisplatin chemotherapy 56 gastrin 56 breast tumors 56 imetelstat 56 chemoradiotherapy 56 neuroblastoma cells 56 neoadjuvant chemotherapy 56 miR #a [002] 56 temsirolimus 56 DLBCL 56 intratumoral injection 56 metastatic RCC 56 EGFR inhibitors 56 gemcitabine 56 TNFα 56 acute myelogenous leukemia AML 56 proto oncogene 56 β amyloid 56 E cadherin 56 DHFR 56 p# protein 56 ubiquitination 56 microglial activation 56 5FU 56 bevacizumab 56 FLT3 56 motor neuron degeneration 56 effector function 56 PXD# 56 tumor metastasis 56 cabazitaxel 56 KRAS mutations 56 NF1 55 immunoreactivity 55 EGFR mutations 55 metastatic malignant 55 fibrosis 55 induced apoptosis 55 PIK3CA 55 Th1 cells 55 PI3K Akt 55 castration resistant prostate cancer 55 PCa 55 lymphoid 55 cellular pathways 55 myelination 55 tumor angiogenesis 55 GLI1 55 oncogenic 55 endostatin 55 glioma cells 55 temozolomide 55 preoperative chemotherapy 55 renal fibrosis 55 mitochondrial fusion 55 locoregional 55 HCV replication 55 follicular lymphoma 55 liver metastasis 55 VEGF receptor 55 tumor necrosis 55 angiogenesis inhibitor 55 Bortezomib 55 neurotoxicity 55 autocrine 55 TAp# 55 atherosclerotic disease 55 BRAF mutation 55 chemoradiation 55 gefitinib 55 Bcr Abl 55 PTPN# 55 neoadjuvant 55 hypermethylation 55 HER2 overexpression 55 GM CSF 55 HER2 receptor 55 induce apoptosis 55 TNF antagonist 55 breast cancer metastasis 55 miR #a [001] 55 hematopoietic 55 cytogenetic response 55 tau protein 55 recombinant erythropoietin 55 aromatase 55 neoplastic 55 CCN2 55 docetaxel chemotherapy 55 gefitinib Iressa 55 IL 1ß 55 etoposide 55 ErbB2 55 EGFR receptor 55 mutant p# 55 FasL 55 esophageal carcinoma 55 cyclooxygenase 2 55 telomerase activity 55 HER2 positive metastatic breast 55 serous ovarian cancer 55 lymphangiogenesis 55 ERCC1 55 tubulin polymerization 55 autoantibody 55 carcinogenesis 55 neuronal dysfunction 55 axitinib 55 cisplatin resistant 55 Bcl 2 55 Akt 55 interferon IFN 55 melanocyte 55 neointimal 55 EGFR pathway 55 tumor regressions 55 gene amplification 55 leukemia ALL 55 histologic 55 Foxp3 55 hedgehog pathway 55 myeloproliferative diseases 55 ERK pathway 55 metastatic tumors 55 carcinoma 55 fibrinolysis 55 metastatic kidney 55 CEACAM1 55 biochemical relapse 55 SOD1 55 tumor suppressor protein 55 HbF 55 estrogen receptor beta 55 TGF beta signaling 55 CMV disease 55 mutant protein 55 intracellular 55 Imatinib 55 S#A# [002] 55 oncogene 55 spermatogenesis 55 IFN alpha 55 erythropoiesis 55 hTERT 55 cardiotoxicity 55 NFkB 55 pathologic 55 hedgehog signaling 55 bleomycin 55 response CCyR 55 Hedgehog pathway 55 caveolin 55 antitumor effects 55 tumor malignancies 55 Xanafide 55 biochemical recurrence 54 colorectal tumor 54 senescent cells 54 GSTP1 54 medulloblastoma 54 inflammatory cytokines 54 airway remodeling 54 antitumor effect 54 chemoresistant 54 PC# cells 54 FGFR2 54 B7 H3 54 CsA 54 doxorubicin 54 Raf MEK ERK 54 Flt3 54 autophagic 54 Doxil ® 54 cancer mCRC 54 tyrosine kinase inhibitor 54 depsipeptide 54 breast carcinoma 54 overexpressing 54 induces apoptosis 54 lymph node metastases 54 Stat5 54 glucocorticoids 54 EGFR mutation 54 kinase pathway 54 PKCi 54 c MET 54 retinoic acid 54 proteinuria 54 Pten 54 mTOR inhibitors 54 p#NTR 54 pegylated liposomal doxorubicin 54 NF kB 54 transmembrane receptor 54 chemotherapeutic agent 54 mycophenolate mofetil 54 solid tumors 54 proapoptotic 54 mesothelin 54 gamma secretase 54 BMP signaling 54 hematopoietic stem cell 54 amyloid β 54 E cadherin expression 54 tyrosine phosphorylation 54 IGFBP 54 caspase activation 54 alemtuzumab 54 HDAC 54 pro angiogenic 54 atherosclerotic lesions 54 B Raf 54 aberrant activation 54 HER2 negative 54 p# [001] 54 plasma kallikrein 54 NKT cells 54 mRCC 54 antiplatelet therapy 54 Vidofludimus 54 Skp2 54 molecularly targeted 54 transcriptional regulation 54 epithelial 54 DAPT 54 anticancer activity 54 GRN#L 54 tumor suppressor genes 54 immune reconstitution 54 nonsense mutation 54 androgen receptor signaling 54 p#Kip# 54 APOPTONE 54 tyrosine kinase inhibitors 54 TGF beta 54 lymphomas 54 microglial 54 vWF 54 HER2/neu 54 ERK signaling 54 SOCS1 54 progression TTP 54 TRAIL induced apoptosis 54 lactate dehydrogenase LDH 54 Myc 54 inflammatory mediators 54 platelet activation 54 Wnt pathway 54 MUC1 54 azacitidine 54 interferon 54 Dasatinib 54 CTLA 4 54 IFN α 54 KRAS mutant tumors 54 epirubicin 54 chlorambucil 54 erythropoietic 54 BCL2 54 mRNA 54 androgen receptor AR 54 p# Shc 54 oncogenesis 54 antitumor efficacy 54 virologic response 54 stem cell differentiation 54 relapsed ovarian cancer 54 demyelination 54 matrix metalloproteinases 54 apoE 54 IFN beta 54 FTY# 54 murine 54 carcinomas 54 HER2 positive breast cancer 54 ADAM# 54 serum phosphate 54 mTOR 54 HIF 1alpha 54 bladder cancers 54 cell lymphoma CTCL 54 radiographic progression 54 factor HGF 54 leukemia AML 54 NRG1 54 EGFRvIII 54 Cyclin E 54 docetaxel 54 NQO1 54 CA4P 54 Neoadjuvant 54 zoledronic acid 54 tau phosphorylation 54 cell adhesion 54 Gefitinib 54 CaP 54 prostate adenocarcinoma 54 tumoral 54 HER2 expression 54 Fludara 54 epithelial cell 54 PTHrP 54 prostate epithelial cells 54 acute GvHD 54 CDK inhibitor 54 protein synthesis 54 myelodysplastic syndromes MDS 54 H. pylori eradication 54 LRP6 54 trastuzumab Herceptin ® 54 HNSCC 54 P cadherin 54 Src 54 hepatocellular carcinomas 54 endothelial cell 54 FUS1 54 uPA 54 erlotinib 53 EGFR tyrosine kinase inhibitors 53 TGF beta pathway 53 VEGF expression 53 CK2 53 cAMP 53 anaplastic lymphoma kinase 53 epidermal growth 53 NF kappaB pathway 53 AAV2 53 BACE1 53 vandetanib 53 platelet reactivity 53 mitochondrial respiration 53 anti apoptotic proteins 53 tumor suppressor gene 53 B7 H1 53 plasma uric acid 53 TET2 53 ADPKD 53 rituximab 53 median PFS 53 pro inflammatory cytokines 53 nilotinib 53 FGFR1 53 cyclin 53 Telintra 53 neutrophil 53 mutational status 53 dephosphorylation 53 ERBB2 53 HER3 53 pancreatic tumor 53 Fas ligand 53 Overexpression 53 intracellular signaling 53 MetMAb 53 Wnt 53 MGd 53 grade gliomas 53 noncancerous cells 53 IFN γ 53 transcriptional repressor 53 caveolin 1 53 liver fibrosis 53 N Myc 53 mTOR pathway 53 seliciclib 53 papillary renal cell carcinoma 53 Cisplatin 53 etanercept 53 MAPK 53 adjuvant chemotherapy 53 Abeta 53 colorectal cancer CRC 53 gastrointestinal stromal tumors GISTs 53 gastric adenocarcinoma 53 NFκB 53 prostate cancer AIPC 53 Hedgehog signaling pathway 53 BCL#A 53 HER2 53 JAK2 53 predictive biomarker 53 synaptogenesis 53 TGF ß1 53 malignant tumors 53 gemcitabine Gemzar 53 operable breast cancer 53 androgen 53 systemic toxicity 53 c Myc 53 SUTENT 53 thromboembolic events 53 BMP4 53 rapamycin 53 Fludarabine 53 EGFR gene 53 Alu RNA 53 lymphoid cells 53 CD#L 53 tumor antigen 53 antibody responses 53 estrogen receptor alpha 53 LKB1 53 activated lymphocytes 53 RASSF1A 53 CCyR 53 chemosensitivity 53 AT1R 53 p# MAPK 53 anti apoptotic 53 node metastases 53 ovarian function 53 hematologic toxicity 53 colorectal adenomas 53 E selectin 53 interferon alfa 53 alkylating agent 53 receptor activation 53 neoplastic cells 53 hepatocellular carcinoma HCC 53 antitumor 53 Metastatic 53 androgen independent 53 IFNg 53 insulin secretion 53 DFMO 53 LRRK2 53 GISTs 53 neoplasm 53 adjuvant therapy 53 radiosensitivity 53 histone deacetylases 53 hepatocyte growth 53 platelet inhibition 53 axonal degeneration 53 malignant cells 53 DMARD 53 PlGF 53 locoregional disease 53 tumor regrowth 53 medullary thyroid cancer 53 tamoxifen therapy 53 microRNA miR 53 neointimal hyperplasia 53 proteolysis 53 micrometastases 53 EGFR expressing 53 factor receptor EGFR 53 keratinocyte 53 MMP9 53 goserelin 53 deacetylation 53 malignancy 53 suppressor cells 53 lymphocyte 53 cancerous cells 53 factor PlGF 53 estrogen receptor progesterone receptor 53 RANK ligand 53 androgen ablation 53 NMDA receptor 53 TGF β1 53 mitotic 53 interferon therapy 53 inhibitory activity 53 p# gene 53 precursor lesions 53 EBRT 53 costimulation 53 NFAT 53 hepatic 53 prognostic factor 53 Eg5 53 CD4 + CD# 53 SUVmax 53 endometrial 53 Prox1 53 HGF 53 chemopreventive agent 53 Stat3 53 gastric carcinoma 53 TIMP 53 mg kg dose 53 IV NSCLC 53 sulfasalazine 53 TGF ß 53 upregulating 53 paricalcitol 53 immune responses 53 Apoptosis 53 NF kappaB activation 53 protein tau 53 oral JAK1 53 calcineurin 53 related apoptosis inducing 53 HepG2 cells 53 isoform 53 CD# + [002] 53 tumor suppressor 53 cytostatic 53 tumorigenic 53 fibrotic disease 53 systemically administered 53 myeloproliferative disorders 53 mRNAs 53 inducible nitric oxide synthase 53 adriamycin 53 glucocorticoid 53 HIF 1a 53 p# mutations 53 cranial irradiation 53 mammary tumor formation 53 K ras mutations 53 PARP inhibition 53 GBM tumors 53 glucocorticoid receptor 53 Kupffer cells 53 panobinostat 53 posaconazole 53 EGFR protein 53 ENaC 53 olaparib 53 Notch signaling 53 carcinoid 53 suppresses tumor 53 sirolimus 53 lobular carcinoma 53 glomerular filtration 53 leukemic stem cells 53 cholangiocarcinoma 53 beta1 integrin 53 corticosteroid therapy 53 lymph node involvement 53 virologic failure 53 BRAF gene 53 FLT3 ITD 53 xenograft tumors 53 breast cancer recurrence 53 anaplastic 53 adipogenic 53 liver histology 53 endometrial carcinoma 53 pomalidomide 53 tubulin 53 chromosomal rearrangement 53 sorafenib Nexavar 53 pDC 53 proteoglycan 53 neoplastic lesions 53 cystatin C 53 cyclin dependent kinases CDKs 53 miR #b [001] 53 ABCB1 53 antiangiogenic therapy 53 fibrosis progression 53 hematologic malignancies 53 bronchopulmonary dysplasia 53 TOP2A 53 Rab5 53 beta catenin protein 53 5 FU 53 castrated mice 52 Wnt signaling pathway 52 prostate carcinoma 52 NF κB 52 cediranib 52 gastrointestinal stromal tumor 52 survivin 52 Bevacizumab 52 leflunomide 52 heterodimers 52 BH4 52 MGMT gene 52 KIT mutations 52 acetylation 52 mediated apoptosis 52 ximelagatran 52 adrenergic receptors 52 UCP2 52 downregulated 52 adefovir 52 locoregional recurrence 52 HER2 receptors 52 axonal regeneration 52 serum calcium levels 52 mesenchymal cell 52 ErbB2 positive 52 CagA 52 cytokine 52 carboplatin paclitaxel 52 tumorigenicity 52 FOLFIRI 52 TGF b 52 IGF1 52 cultured cells 52 pertuzumab 52 TGFß 52 MGUS 52 cytopenias 52 vascularization 52 β cell 52 prostate cancer CRPC 52 tumor xenograft models 52 oncogenic transformation 52 metastatic bladder 52 oncogenes 52 thalidomide Thalomid 52 MUC1 * 52 uPAR 52 axonal 52 anti fibrotic 52 ß catenin 52 CD# [002] 52 ABCA1 52 nonsmall cell lung cancer 52 leukaemic cells 52 fibrinolytic 52 HIF 1α 52 receptor tyrosine kinase inhibitor 52 sustained virologic response 52 histone acetylation 52 inducing apoptosis 52 rhTSH 52 catenin 52 epithelia 52 hippocampal neurons 52 haematopoietic 52 Hydroxyurea 52 neuroinflammatory 52 sustained virological response 52 IL 1β 52 K ras 52 Erlotinib 52 inhibits tumor 52 androgen suppression therapy 52 viral kinetics 52 DLC1 52 gastric cancer 52 prognostic indicator 52 inflammatory cytokine 52 TGFb 52 microalbuminuria 52 prostate tumors 52 homodimer 52 glioblastomas 52 methylation 52 NKG2D 52 Irinotecan 52 phosphorylate 52 EGFR HER2 52 IGF IR 52 #ME# 52 multiple myeloma MM 52 hepatic fibrosis 52 signaling pathways 52 chemotherapeutic drug 52 telomere lengths 52 thyroglobulin 52 alpha synuclein 52 FOLFOX4 52 ovarian tumors 52 S#K# 52 lymphocytes 52 adjuvant therapies 52 acinar 52 EpCAM 52 taxane therapy 52 PTEN protein 52 CCR2 52 vimentin 52 ON #.Na 52 constitutively active 52 tyrosine kinase 52 gene p# 52 coadministration 52 adenocarcinomas 52 G CSF 52 hypercalcemia 52 factor G CSF 52 apoptosis programmed cell 52 menin 52 XBP1 52 free survival PFS 52 HGPIN 52 estrogen receptors 52 ectopic expression 52 RBP4 52 Phosphorylation 52 taxanes 52 LNCaP cells 52 TGFβ 52 integrin 52 multikinase inhibitor 52 cytotoxic 52 synapse formation 52 NADPH oxidase 52 HPA axis 52 autophagy 52 hepatocyte 52 HIV RNA 52 hormone LHRH agonist 52 estramustine 52 astrocytes 52 upregulation 52 PP2A 52 Smoothened 52 endothelial 52 phosphatidylinositol 3 52 chromosomal instability 52 remission CR 52 CatB 52 LRP5 52 selective inhibition 52 androgen suppression 52 viral replication 52 Torisel 52 TTR gene 52 EGF receptors 52 proinflammatory cytokines 52 fibrogenesis 52 histologies 52 bicalutamide 52 HBV replication 52 melanoma tumors 52 neurocognitive function 52 IFRD1 52 paclitaxel 52 mitochondrial dysfunction 52 FOLFOX 52 pheochromocytoma 52 advanced adenomas 52 relapsed SCLC 52 CTAP# Capsules 52 complete remissions 52 abiraterone 52 costimulatory 52 β cells 52 renal function 52 carcinoids 52 myocardial reperfusion 52 proteasome 52 epigenetic mechanisms 52 neoadjuvant treatment 52 perioperative complications 52 Symadex 52 kinase inhibitor 52 EpCAM expression 52 pazopanib 52 HSCT 52 genotypic resistance 52 HDAC2 52 FGFR3 52 prognostic significance 52 metastatic malignant melanoma 52 CR CRu 52 TCF#L# 52 adalimumab 52 eNOS 52 advanced NSCLC 52 HuR 52 VEGFR 52 lung metastases 52 cell signaling pathways 52 hCG beta 52 STAT1 52 lupus nephritis 52 malignant growths 52 monoclonal gammopathy 52 gastric atrophy 52 eotaxin 52 mammary cells 52 insulin sensitizing 52 RhoA 52 cyclin B1 52 cardiomyocyte 52 Lyn kinase 52 colorectal cancer 52 B lymphocytes 52 hypoxia inducible factor 52 NPD1 52 Sertoli cell 52 premalignant 52 osteoclast formation 52 Trastuzumab 52 tumor xenografts 52 heavily pretreated patients 52 HER2 positive 52 chronic lymphocytic leukemia CLL 52 mTORC1 52 biliary tract cancer 52 anthracyclines 52 mammographic density 52 hepatoma 52 chemotherapeutic 52 TIMP 1 52 N myc 52 renal toxicity 52 TNF inhibitors 52 angiogenesis 52 PTEN gene 52 NMDA receptors 52 elesclomol 52 CAG repeats 52 paclitaxel Taxol 52 Taxotere ® 52 genomic instability 52 ERK2 52 prostaglandin synthesis 52 mesenchymal cells 52 MYCN 52 PNH patients 52 myeloid 52 T1DM 52 Htt 52 poorer prognosis 52 TGF beta1 52 Preclinical studies 52 metastatic melanomas 52 chemo radiotherapy 52 STAT4 52 hepatic metastases 52 paracrine 52 ara C 52 Th2 cytokines 52 Abeta# 52 bosentan